1. Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia
- Author
-
Suzanne O. Arulogun, Duncan Brian, Harshita Goradia, Aaron Cooney, Tobias Menne, RayMun Koo, Aideen T. O'Neill, Josephine M. I. Vos, Guy Pratt, Deborah Turner, Kirsty Marshall, Kate Manos, Claire Anderson, Maria Gavriatopoulou, Charalampia Kyriakou, Marie J. Kersten, Monique C. Minnema, Eirini Koutoumanou, Dima El‐Sharkawi, Kim Linton, Dipti Talaulikar, Helen McCarthy, Mark Bishton, George Follows, Ashutosh Wechalekar, Shirley P. D'Sa, Clinical Haematology, General Internal Medicine, AII - Cancer immunology, CCA - Cancer biology and immunology, and CCA - Cancer Treatment and Quality of Life
- Subjects
Hematology - Abstract
Bendamustine and rituximab (BR) therapy is commonly used in the treatment of Waldenström Macroglobulinemia (WM). The impact dose of Bendamustine dose on response and survival outcomes is not well-established, and the impact of its use in different treatment settings is not clear. We aimed to report response rates and survival outcomes following BR, and clarify the impact of depth of response and bendamustine dose on survival. A total of 250 WM patients treated with BR in the frontline or relapsed settings were included in this multicenter, retrospective cohort analysis. Rates of partial response (PR) or better differed significantly between the frontline and relapsed cohorts (91.4% vs 73.9%, respectively; p < 0.001). Depth of response impacted survival outcomes: two-year predicted PFS rates after achieving CR/VGPR vs PR were 96% versus 82%, respectively (p = 0.002). Total bendamustine dose was predictive of PFS: in the frontline setting, PFS was superior in the group receiving ≥1000 mg/m2 compared with those receiving 800–999 mg/m2 (p = 0.04). In the relapsed cohort, those who received doses of
- Published
- 2023